Good evening and welcome to Markets Desk, your close-of-day read on what moved markets and why.
The bond market is sending a clear warning signal. The ten-year Treasury yield climbed to its highest level since two thousand two Thursday, as a global selloff in sovereign debt continues to gather momentum. With jobs data still ahead, traders are pricing in a higher-for-longer rate environment, and that pressure is rippling across equities and credit alike.
Turning to the pharmaceutical space, Zealand Pharma delivered a significant catalyst for the obesity drug landscape. Boehringer Ingelheim's survodutide met its co-primary endpoints in a Phase three trial targeting adults with obesity and type two diabetes. That result broadens the competitive field in a sector already reshaped by GLP-one drugs, and investors will be watching how this affects the broader weight-loss drug race.
And speaking of GLP-ones reshaping industries, McDonald's is reportedly exploring an eight-point-five billion dollar overhaul over the next decade, internally dubbed McDonald's Next. The fast food giant is considering smaller portions and protein-forward options aimed directly at GLP-one users and health-conscious consumers, a striking strategic pivot from the chain that once made supersizing its calling card.
That's the tape. Markets Desk, signing off the floor.
